You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,165,716

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,165,716

Title:	Screening for disorders of serotonergic dysfunction
Abstract:	Three novel alleles of the serotonin transporter gene are disclosed and shown to be effective markers for screening and diagnosis of migraine and psychiatric disorders. The sequences of the alleles are given. Methods for in vitro screening of individuals using DNA taken from blood samples are taught.
Inventor(s):	Battersby; Sharon (Edinburgh, GB), Fink; George (Edinburgh, GB), Goodwin; Guy Manning (Edinburgh, GB), Harmar; Anthony John (Edinburgh, GB), Ogilvie; Alan David (Edinburgh, GB), Smith; Christopher Albert Dale (Edinburgh, GB)
Assignee:	Medical Research Council (London, GB)
Application Number:	09/043,507
Patent Claims:	1. A method of diagnosis of migraine or bipolar disorder or unipolar depression, or of susceptibility thereof in a human patient, said method comprising obtaining a sample of genetic material from said patient, analysing the number of copies of one or more alleles selected from the group consisting of STin2.9 (SEQ ID No. 1), Stin2.10 (SEQ ID No. 2) and Stin2.12 (SEQ ID No. 3) of the VNTR region in the second intron of the serotonin transporter gene present in said genetic material, wherein said number of copies indicates the likelihood of the patient suffering from migraine or bipolar disorder or unipolar depression. 2. A method as claimed in claim 1, wherein said method analyses the number of copies of one or more alleles selected from the group consisting of STin2.9 (SEQ ID NO 1), STin2.10 (SEQ ID NO 2) and STin2.12 (SEQ ID NO 3), and wherein the presence of STin2.9 (SEQ ID NO 1) indicates that the patient is at risk of or suffering from bipolar disorder or unipolar depression or MA migraine and wherein the presence of STin2.12 (SEQ ID NO 3) indicates that the patient is at risk of or suffering from MO migraine. 3. A method as claimed in claim 1 or claim 2 wherein the number of VNTR repeats or said alleles occurring in intron 2 of the serotonin transporter gene is determined in vitro. 4. A method as claimed in claims 1 or 2, wherein the number of VNTR repeats or the presence of said alleles is determined using one or more techniques selected from the group consisting of polymerase chain reaction, heteroduplex analysis, comparative genome hybridisation, single stand conformational polymorphism analysis, ligase chain reaction and Southern blotting. 5. A method as claimed in claim 1 or 2 wherein the sample comprises body tissue or body fluids containing DNA. 6. A method of diagnosis of migraine or bipolar disorder or unipolar depression or of susceptibility thereof by analysing the number of human VNTR repeats in the second intron of the serotonin transporter gene.

Details for Patent 6,165,716

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2015-09-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2015-09-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2015-09-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.